Furthermore, among YPM who had either complete or partial response to anthracycline-based neoadjuvant chemotherapy, 80.95% had TNBC or HER2 subtypes, while 19.1% had luminal breast cancer For postmenopausal women with either complete clinical response or partial response, 77.42% had TNBC or HER2+ subtype and 22.6% Luminal A and B These results are consistent with reports from a study done by Carey et al. indicating that Basal-like and HER- molecular subtypes are more sensitive to anthracycline-based neoadjuvant chemotherapy than luminal breast cancers60. This evidence concerns the gene ERBB2 and breast carcinoma.